Nolvadex 20 mg is an oral tamoxifen citrate tablet manufactured by Genshi Labs and dosed at 20 mg per tablet in a 100-tablet pack.
Nolvadex 20 mg contains tamoxifen citrate, a selective estrogen receptor modulator (SERM). Tamoxifen is FDA-approved for the treatment of metastatic breast cancer in women and men, adjuvant therapy for node-positive breast cancer, and reduction of breast cancer incidence in high-risk women. In non-medical bodybuilding settings, tamoxifen is commonly referenced for its anti-estrogenic properties, particularly in the context of managing estrogen-related side effects from anabolic steroid use and in post-cycle therapy protocols.
Tamoxifen works by competitively binding to estrogen receptors in target tissues, where it acts as an antagonist in breast tissue while exhibiting mixed agonist/antagonist activity depending on the tissue. This mechanism allows it to block estrogen's effects in certain tissues without eliminating estrogen entirely. In male bodybuilders, tamoxifen is commonly referenced off-label for preventing or reducing gynecomastia and as part of comprehensive post-cycle hormone recovery programs.
While tamoxifen's medical applications are well established in oncology, its use for physique or performance enhancement falls outside approved medical indications. Tamoxifen carries a boxed warning for increased risk of uterine malignancies, including endometrial cancer and uterine sarcoma, as well as thromboembolic events including stroke, deep vein thrombosis and pulmonary embolism. Non-medical use should be considered in the context of these documented safety concerns.
Tamoxifen citrate is a non-steroidal selective estrogen receptor modulator with a well-characterized pharmacological profile established through decades of clinical use. Its primary mechanism involves competitive binding to estrogen receptors, with tissue-specific effects that distinguish it from aromatase inhibitors.
Tamoxifen belongs to the SERM class of compounds, which are characterized by their ability to produce estrogen-like or anti-estrogenic effects depending on the target tissue. In breast tissue, tamoxifen acts as an estrogen antagonist, blocking estrogen's proliferative effects. This is the basis for its approved use in breast cancer treatment and prevention.
Following oral administration, tamoxifen is extensively metabolized by cytochrome P450 enzymes, including CYP3A, CYP2D6, CYP2C9, and CYP2C19. The metabolites N-desmethyltamoxifen and endoxifen are pharmacologically active, with endoxifen demonstrating significantly greater potency at the estrogen receptor than the parent compound.
Following a single 20 mg oral dose, tamoxifen reaches an average peak plasma concentration of approximately 40 ng/mL, with steady-state concentrations achieved after about 4 weeks of daily administration. The terminal elimination half-life of tamoxifen is approximately 5 to 7 days, while the active metabolite N-desmethyltamoxifen has a half-life of approximately 14 days.
Unlike aromatase inhibitors that reduce estrogen production, tamoxifen blocks estrogen's effects at the receptor level in specific tissues. This distinction is important: tamoxifen does not lower circulating estrogen levels but rather modulates their activity in target tissues.
Genshi Labs offers several products that are commonly referenced alongside tamoxifen in non-medical bodybuilding contexts. For managing estrogen-related side effects during cycles, Arimidex 2 mg (anastrozole) is an aromatase inhibitor that reduces estrogen production, representing a different approach than tamoxifen's receptor blockade.
For post-cycle therapy, Clomid 50 mg (clomiphene citrate) is another SERM frequently compared to tamoxifen. Both compounds are used to support endogenous testosterone recovery, though they differ in their receptor selectivity and side effect profiles. Tamoxifen is often referenced for its breast tissue protection, while Clomid is noted for its effects on LH and FSH signaling.
The information below is provided for educational reference only. Tamoxifen is a prescription medication; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In medically supervised settings, tamoxifen dosing for breast cancer treatment is typically 20 to 40 mg daily, divided into one or two administrations. In non-medical bodybuilding contexts, tamoxifen is commonly referenced at dosages of 10–40 mg per day depending on the intended purpose, whether for on-cycle estrogen management or post-cycle therapy.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Medical (breast cancer) | 20–40 mg daily | Once or twice daily |
| On-cycle (non-medical) | 10–20 mg daily | Once daily |
| PCT (non-medical) | 20–40 mg daily | Once daily, tapered |
In non-medical bodybuilding contexts, tamoxifen is commonly referenced either during a cycle to manage estrogen-related side effects or as part of post-cycle therapy. When used on-cycle, it is typically employed at lower doses for gynecomastia prevention in individuals who are prone to estrogenic side effects.
For post-cycle recovery, tamoxifen is often used alongside or compared to Clomid 50 mg, with some protocols incorporating both SERMs for complementary effects on hormonal recovery. Cycle structure and support protocols should be considered in the context of individual experience, health status and bloodwork where possible.
Tamoxifen is associated with several potential side effects that should be considered. Thromboembolic events, including deep vein thrombosis and pulmonary embolism, are documented risks with tamoxifen therapy and may be relevant in the context of non-medical use. Other commonly reported effects include hot flashes, vaginal discharge, fatigue, and mood changes.
For individuals using tamoxifen in non-medical contexts, monitoring for signs of thromboembolic events and being aware of potential drug interactions is important. Tamoxifen is metabolized by CYP2D6, and concurrent use of strong CYP2D6 inhibitors may affect its metabolism.
After completing a cycle of suppressive compounds, post-cycle therapy is commonly referenced in non-medical bodybuilding contexts to support restoration of endogenous testosterone production. Tamoxifen is one of the SERMs most frequently cited for this purpose, typically at dosages of 20–40 mg daily for 3–4 weeks, often with a tapering approach.
PCT protocols vary based on cycle length, compounds used and individual factors. Bloodwork and, where possible, medical guidance can help inform recovery strategy.
Dosing strategies, support compounds and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Tamoxifen is a prescription medication with a well-documented safety profile established through decades of clinical use. Medical tamoxifen therapy requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Tamoxifen carries a boxed warning for increased risk of uterine malignancies, including endometrial cancer and uterine sarcoma, in women taking the medication. The risk is primarily observed in women over 50 and increases with duration of use.
Thromboembolic events, including stroke, deep vein thrombosis and pulmonary embolism, are also documented risks with tamoxifen therapy. These risks are relevant considerations in any context of tamoxifen use.
Tamoxifen's approved indications are limited to breast cancer treatment and risk reduction in high-risk women. Use for bodybuilding, performance enhancement, or post-cycle therapy falls outside approved medical indications and should be considered in the context of documented safety concerns, including thromboembolic and uterine risks.
The most commonly reported side effect of tamoxifen is hot flashes, experienced by approximately 40% of women in clinical trials. Vaginal discharge, fatigue, and mood disturbances are also commonly reported.
Serious adverse effects include increased risk of endometrial cancer, uterine sarcoma, and thromboembolic events. Visual disturbances, including cataracts and retinal changes, have been reported and may require ophthalmic evaluation.
In men, there is limited reliable information on tamoxifen's side effect profile, though some evidence suggests long-term use may be associated with weight gain and sexual dysfunction.
Tamoxifen is contraindicated in pregnancy and should not be used by women who are pregnant or breastfeeding. Individuals with a history of thromboembolic events or known thrombophilia should discuss tamoxifen use with a healthcare professional.
Pre-existing visual problems, liver disease, and abnormal blood counts should be evaluated before tamoxifen use. Any unusual gynecological symptoms, particularly vaginal bleeding, require prompt medical evaluation.
Medical tamoxifen therapy typically involves regular follow-up to monitor for adverse effects, including gynecological evaluation and ophthalmic examinations where appropriate. Laboratory monitoring may include blood counts and liver function tests.
Laboratory testing of the product itself, such as a published potency report, is separate from clinical monitoring of the person using tamoxifen. No published laboratory report is available for this specific product.
Store at controlled room temperature, 20–25°C (68–77°F), in a well-closed, light-resistant container. Keep all medications out of the reach of children. Follow the storage instructions provided with the product packaging.
Nolvadex 20 mg is supplied through the official Genshi Labs distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Genshi Labs distribution chain.
To verify your Nolvadex 20 mg product, use the security code on the product packaging and cross-check it on the Genshi Labs official site. Official Genshi Labs presentation and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve product integrity and ensure the tablets remain suitable for their intended use throughout their shelf life.
Store tamoxifen tablets at controlled room temperature, 20–25°C (68–77°F), in a well-closed, light-resistant container. Keep the tablets in their original packaging until use to protect them from moisture and contamination.
Do not store in areas subject to temperature extremes, such as bathrooms or near kitchen appliances. Keep out of reach of children and pets.
Answers to common questions about Nolvadex 20 mg, tamoxifen citrate, its mechanisms, dosage considerations and safety information.
Nolvadex 20 mg contains tamoxifen citrate, a selective estrogen receptor modulator. In medical practice, tamoxifen is approved for the treatment and prevention of estrogen receptor-positive breast cancer in women and men. In non-medical bodybuilding settings, it is commonly referenced for managing estrogen-related side effects and in post-cycle therapy protocols, though such use falls outside approved medical indications.
In medical settings, tamoxifen is typically administered once or twice daily depending on the indication, with total daily doses ranging from 20–40 mg. In non-medical contexts, tamoxifen is commonly referenced at dosages of 10–40 mg per day, either as a single daily dose or split into two administrations.
Tamoxifen itself is commonly used as a component of post-cycle therapy in non-medical bodybuilding contexts, rather than requiring its own PCT. After suppressive steroid cycles, tamoxifen is referenced for supporting endogenous testosterone recovery, typically at 20–40 mg daily for 3–4 weeks with a tapering approach. For comparing SERM options, Clomid 50 mg is another compound frequently referenced in PCT protocols.
Tamoxifen citrate is a selective estrogen receptor modulator that binds to estrogen receptors, acting as an antagonist in breast tissue while exhibiting mixed agonist/antagonist effects in other tissues. This mechanism underlies its medical use in breast cancer treatment and prevention. In non-medical contexts, it is referenced for blocking estrogen's effects at the receptor level, particularly in breast tissue.
Following oral administration, tamoxifen reaches peak plasma concentrations at approximately 5 hours, with steady-state levels achieved after about 4 weeks of daily dosing. In medical contexts, therapeutic effects in breast cancer treatment are typically assessed over months rather than days. In non-medical settings, the onset of effects for estrogen management would depend on the specific context and individual response.
There is no single SERM that is universally best. Tamoxifen has the most extensive clinical evidence base of any SERM, with decades of data supporting its use in breast cancer treatment and prevention. Other SERMs such as clomiphene have different receptor selectivity profiles and side effect characteristics, which may make one more suitable than another depending on the specific context.
Both tamoxifen and clomiphene are SERMs, but they differ in receptor selectivity and effects. Tamoxifen is often referenced for its breast tissue protection and is used in medical settings for breast cancer. Clomiphene is more commonly referenced for stimulating LH and FSH output. In non-medical PCT contexts, some protocols incorporate both compounds for complementary effects. Clomid 50 mg by Genshi Labs offers an alternative SERM option.
Tamoxifen and Arimidex (anastrozole) work through entirely different mechanisms. Tamoxifen is a SERM that blocks estrogen receptors, while anastrozole is an aromatase inhibitor that reduces estrogen production by blocking the aromatase enzyme. This fundamental difference means they have distinct applications and side effect profiles. Arimidex 2 mg represents the aromatase inhibitor approach to estrogen management.
In medical contexts, 20 mg daily is a standard dose for tamoxifen, with 40 mg daily representing the upper end of the standard dosing range. In non-medical bodybuilding contexts, 20 mg is commonly referenced in on-cycle protocols, while 40 mg may be used in post-cycle therapy protocols. Whether any dose is appropriate depends on the specific context and individual factors.
Nolvadex 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. It is supplied as 100 oral tablets per package, giving 2,000 mg of total labeled content.
No published laboratory report is available for this specific Nolvadex 20 mg product at this time. Laboratory testing of pharmaceutical products can provide information about potency and purity, but such testing is separate from clinical monitoring of individuals using these compounds.
Tamoxifen is FDA-approved for use in women for breast cancer treatment and risk reduction. In non-medical contexts, its use by women for physique enhancement falls outside approved indications and carries risks including uterine malignancies and thromboembolic events. Any consideration of tamoxifen use by women should involve careful evaluation of risks.